Perspective Therapeutics, Inc.CATXNYSE
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | -100.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +28.64% | +46.15% | +6.04% | +5.19% | +4.51% |
| Weighted Average Shares Diluted Growth | +28.64% | +46.15% | +6.04% | +5.19% | +4.51% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | -255.85% | +0.00% | -584.02% | +0.00% |
| Free Cash Flow Growth | +0.00% | -649.37% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +26.21% | -92.19% | +58.45% | -17.51% | -99.60% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | +248.45% | +18.35% | -19.48% | -24.63% | -21.73% |
| Book Value per Share Growth | +200.56% | -15.28% | -26.52% | -29.90% | -31.85% |
| Debt Growth | +59.23% | +32.66% | -7.90% | -22.38% | -59.92% |
| R&D Expense Growth | +111.89% | +92.32% | +31.26% | +69.10% | +155.56% |
| SG&A Expenses Growth | +386.78% | +33.41% | +39.81% | +10.84% | -15.70% |